Edition:
India

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

0.70USD
8:15pm IST
Change (% chg)

$0.00 (+0.57%)
Prev Close
$0.70
Open
$0.70
Day's High
$0.70
Day's Low
$0.69
Volume
13,800
Avg. Vol
46,141
52-wk High
$8.00
52-wk Low
$0.65

Select another date:

Tue, Mar 27 2018

BRIEF-Altimmune Announces Positive Data From Its Phase 2A Study Of Nasovax Intranasal Influenza Vaccine

* ALTIMMUNE ANNOUNCES POSITIVE DATA FROM ITS PHASE 2A STUDY OF NASOVAX INTRANASAL INFLUENZA VACCINE AND PROVIDES AN UPDATE ON ITS PHASE 1B STUDY OF HEPTCELL TARGETED IMMUNOTHERAPY IN CHRONIC HEPATITIS B INFECTION

BRIEF-Altimmune Announces Pre-Clinical Data From Its Sparvax-L Anthrax Vaccine Program

* ALTIMMUNE ANNOUNCES PRE-CLINICAL DATA FROM ITS SPARVAX-L ANTHRAX VACCINE PROGRAM

BRIEF-Hudson Bay Capital Management Reports A 9.99 Percent Passive Stake In Altimmune

* HUDSON BAY CAPITAL MANAGEMENT LP‍ REPORTS A 9.99 PERCENT PASSIVE STAKE IN ALTIMMUNE, INC​ AS OF DECEMBER 31, 2017 - SEC FILING Source text for Eikon: [http://bit.ly/2nwUAiB] Further company coverage:

BRIEF-Altimmune Announces Allowance On Patent Covering Use Of Nasoshield In U.S.

* ALTIMMUNE ANNOUNCES NOTICE OF ALLOWANCE ON PATENT COVERING USE OF NASOSHIELD IN THE U.S. Source text for Eikon: Further company coverage:

BRIEF-Altimmune Elects Mitchel Sayare As Chairman Of Its Board

* ALTIMMUNE ELECTS MITCHEL SAYARE, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS

BRIEF-Altimmune reports Q3 loss per share $2.05

* Altimmune announces third quarter 2017 financial results and provides corporate update

Select another date: